Ivor

Bemiparin Sodium, the active ingredient in Ivor, is a low molecular weight heparin presented as a subcutaneous injection for subcutaneous use. It is employed to prevent and treat thromboembolic disorders such as deep vein thrombosis and pulmonary embolism in patients at risk, including those undergoing surgery or experiencing prolonged immobilisation.

GNH USA supplies Ivor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other regulated markets, ensuring product quality and regulatory compliance.

Bemiparin Sodium is indicated for several thromboembolic conditions, acting primarily to prevent clot formation. - Deep vein thrombosis (prevention): reduces incidence of postoperative DVT in surgical patients. - Deep vein thrombosis (treatment): facilitates resolution of acute DVT by inhibiting further clot propagation. - Pulmonary embolism (prevention): lowers risk of PE in high‑risk medical patients. - Thromboembolic prophylaxis in medical patients: prevents clot events in immobilised or critically ill individuals.

Bemiparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or erythema: mild discomfort or redness at the injection site. - Bruising or hematoma: localized bleeding under the skin. - Minor bleeding: such as epistaxis or gum bleeding. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Major bleeding: gastrointestinal, intracranial or surgical site hemorrhage. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet count drop. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Skin necrosis: severe local tissue damage. - Spinal or epidural hematoma: risk after neuraxial procedures. - Thrombosis paradoxically: rare clot formation despite therapy.

Before initiating Bemiparin Sodium, several precautionary measures should be considered to minimise risk. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: use with caution in severe liver disease due to altered metabolism. - Concomitant anticoagulants or antiplatelet agents: increased bleeding risk; monitor coagulation parameters. - Recent surgery or trauma: assess bleeding risk before administration. - Pregnancy: category B; use only if potential benefit justifies potential risk to the fetus. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Bemiparin Sodium can interact with several medicines, affecting its anticoagulant effect or bleeding risk.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulation may cause severe bleeding. - Antiplatelet drugs (aspirin, clopidogrel): heightened bleeding tendency. - Thrombolytic agents (alteplase, streptokinase): risk of uncontrolled hemorrhage. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding. - Neuraxial anesthesia or spinal puncture: potential for spinal hematoma.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may potentiate hypotensive effects when combined with bleeding. - Corticosteroids: can exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding risk. - Selective COX‑2 inhibitors (celecoxib): similar bleeding considerations. - Heparin flush solutions: cumulative heparin exposure may affect platelet counts.